Literature DB >> 16087181

The role of PKCalpha and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer.

Sharad S Singhal1, Sushma Yadav, Jyotsana Singhal, Kenneth Drake, Yogesh C Awasthi, Sanjay Awasthi.   

Abstract

In deletion mutant analyses of potential phosphorylation sites in RLIP76, we identified T297 and S509 as targets for phosphorylation by PKCalpha. Phosphorylation at T297 increased doxorubicin (DOX)-transport activity approximately 2-fold for RLIP76 purified from recombinant source, or from three small (H69, H1417, H1618) and three non-small cell, one each derived from H226 (squamous), H358 (bronchio alveolar), and H1395 (adenocarcinoma) lung cancer cell lines. T297 phosphorylation conferred sensitivity to tryptic digestion at R293. The specific activity for DOX-transport by RLIP76 purified from non-small cell, which was primarily in the phosphorylated form, was approximately twice that in small cell lung cancer cell lines. These finding offer a novel explanation for the observed intrinsic differences in sensitivity to DOX between non-small cell and small cell lung cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087181     DOI: 10.1016/j.febslet.2005.07.032

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  Role of RLIP76 in doxorubicin resistance in lung cancer.

Authors:  Rit Vatsyayan; Pankaj Chaudhary; Poorna Chandra Rao Lelsani; Preeti Singhal; Yogesh C Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

2.  Targeting p53-null neuroblastomas through RLIP76.

Authors:  Jyotsana Singhal; Sushma Yadav; Lokesh Dalasanur Nagaprashantha; Rit Vatsyayan; Sharad S Singhal; Sanjay Awasthi
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-16

3.  Mitogenic and drug-resistance mediating effects of PKCalpha require RLIP76.

Authors:  Sharad S Singhal; Sushma Yadav; Jyotsana Singhal; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Biochem Biophys Res Commun       Date:  2006-07-28       Impact factor: 3.575

4.  Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis.

Authors:  Sharad S Singhal; Dilki Wickramarachchi; Sushma Yadav; Jyotsana Singhal; Kathryn Leake; Rit Vatsyayan; Pankaj Chaudhary; Poorna Lelsani; Sumihiro Suzuki; Shaohua Yang; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

Review 5.  RLIP76 Targeted Therapy for Kidney Cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; James Figarola; David Horne; Sanjay Awasthi
Journal:  Pharm Res       Date:  2015-05-29       Impact factor: 4.200

Review 6.  RLIP76: A novel glutathione-conjugate and multi-drug transporter.

Authors:  Sharad S Singhal; Sushma Yadav; Cherice Roth; Jyotsana Singhal
Journal:  Biochem Pharmacol       Date:  2008-10-15       Impact factor: 5.858

Review 7.  RLIP76 and Cancer.

Authors:  Sanjay Awasthi; Sharad S Singhal; Yogesh C Awasthi; Bryan Martin; Jung-Hee Woo; C Casey Cunningham; Arthur E Frankel
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

Review 8.  RLIP76: a versatile transporter and an emerging target for cancer therapy.

Authors:  Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sanjay Awasthi; Sharad S Singhal
Journal:  Biochem Pharmacol       Date:  2010-01-25       Impact factor: 5.858

9.  Mass spectroscopic phosphoprotein mapping of Ral binding protein 1 (RalBP1/Rip1/RLIP76).

Authors:  Mikael C Herlevsen; Dan Theodorescu
Journal:  Biochem Biophys Res Commun       Date:  2007-08-08       Impact factor: 3.575

10.  MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN.

Authors:  Ping Ren; Fangchao Gong; Yan Zhang; Jindong Jiang; Hong Zhang
Journal:  Tumour Biol       Date:  2015-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.